Clinical efficacy of low dose recombinant tissue-type plasminogen activator for the treatment of acute intermediate-risk pulmonary embolism

A great resolution of the thrombus was confirmed by CTPA A) before and B) after the thrombolytic therapy (30 mg rt-PA IV over 2 hours) in a 75-year-old acute intermediate-risk PE woman. A little resolution of the thrombus was confirmed by CTPA C) before and D) after the thrombolytic therapy (30 mg rt-PA IV over 2 hours) in a 78-year-old acute intermediate-risk PE man.